TSX runs higher on rate cut expectations
DUBLIN - Investment firm Citadel Group has disclosed a 1.44% stake in Mural Oncology plc, according to a regulatory filing published Wednesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 250,485 shares representing 1.44% of Mural Oncology, alongside short positions equivalent to 0.99% of the company.
The filing details Citadel’s position as of August 19, which includes 221,885 relevant securities owned or controlled, representing 1.28% of Mural Oncology’s common stock. Additionally, the firm holds stock-settled derivatives including options amounting to 28,600 shares or 0.16%.
The disclosure also reveals multiple transactions conducted by Citadel on August 19, including purchases of Mural Oncology shares at prices ranging from $1.77 to $1.82 per share, and sales at similar price points.
The filing includes details of Citadel’s options positions, with purchased put options for 91,200 shares at various strike prices and expiration dates, as well as call options for 27,600 shares. The firm has also sold call options for 81,700 shares.
Irish Takeover Panel rules require disclosure of positions representing 1% or more in companies that may be involved in takeover situations. The disclosure was made through a Form 8.3 filing, which is used for opening position disclosures and dealing disclosures.
Mural Oncology is listed on the Irish stock exchange with shares trading under the ISIN code IE000LK2BOB4.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.